Cholinergic Stimulation by Pyridostigmine Bromide Before Myocardial Infarction Prevent Cardiac and Autonomic Dysfunction

Imagem de Miniatura
Arquivos
art_BARBOZA_Cholinergic_Stimulation_by_Pyridostigmine_Bromide_Before_Myocardial_Infarction_2019.PDF (1.43 MB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
BARBOZA, C. A.
FUKUSHIMA, A. R.
CARROZZI, N.
MACHI, J. F.
MOSTARDA, C. T.
NATHANSON, L.
MORRIS, M.
CAPERUTO, E. C.
Citação
SCIENTIFIC REPORTS, v.9, article ID 2481, 11p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Inflammatory processes and cardiovascular autonomic imbalance are very relevant characteristic of the enormous dynamic process that is a myocardial infarction (MI). In this sense, some studies are investigating pharmacological therapies using acetylcholinesterase inhibitors, such as pyridostigmine bromide (PYR), aiming to increase parasympathetic tone after MI. Here we hypothesized that the use of PYR before the MI might bring an additional positive effect to the autonomic function, and consequently, in the inflammatory response and cardiac function. The present study aimed to evaluate left ventricular function, baroreflex sensitivity, autonomic modulation, and inflammatory profile in PYR- treated rats previously to MI. Methods: Male Wistar rats (250-300 g) were treated for 60 days with PYR. After treatment, they were submitted to the MI. After the MI, the autonomic and ventricular function were evaluated, as well as the systemic, left ventricle, and adipose tissue inflammatory profile. Results: PYR, performed before MI, prevented HR increase, systolic function impairment, baroreflex sensitivity drop, as well as pulse interval variance, RMSSD, blood pressure and parasympathetic modulation reduction in treated rats compared to untreated rats. Also, this positive functional changes may have been a result of the reduced inflammatory parameters in the left ventricle (IFN-alpha, IL-6, and IL-1 beta), as well as increased IL-10 expression and IL-10/TNF-alpha ratio in treated animals before MI. Conclusion: Prior treatment with PYR prevents impairment of the autonomic nervous system after MI, which may be associated with the attenuated expression of inflammatory factors and heart dysfunction.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31285
Referências
  1. Androne AS, 2003, HEART, V89, P854, DOI 10.1136/heart.89.8.854
  2. Barboza CA, 2016, INT J SPORTS MED, V37, P421, DOI 10.1055/s-0035-1565136
  3. Barboza C. A., 2017, THESIS
  4. Behling A, 2003, AM HEART J, V146, P494, DOI 10.1016/S0002-8703(03)00319-3
  5. Bezerra O. C., 2017, SCI REP, V20, P1
  6. Chen X, 2017, CELL PHYSIOL BIOCHEM, V43, P915, DOI 10.1159/000481642
  7. Conti FF, 2015, AM J PHYSIOL-REG I, V309, pR1532, DOI 10.1152/ajpregu.00076.2015
  8. de La Fuente RN, 2013, CLIN EXP PHARMACOL P, V40, P610, DOI 10.1111/1440-1681.12121
  9. Feriani D. J., 2018, FRONT PHYSIOL, V12, P9
  10. Feriani DJ, 2017, INT J CARDIOL, V227, P757, DOI 10.1016/j.ijcard.2016.10.061
  11. Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
  12. Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362
  13. La Rovere MT, 1998, LANCET, V351, P478
  14. Lataro RM, 2013, AM J PHYSIOL-REG I, V305, pR908, DOI 10.1152/ajpregu.00102.2013
  15. Lei L, 2004, CIRCULATION, V110, P796, DOI 10.1161/01.CIR.0000138933.85923.36
  16. LEVY MN, 1969, J APPL PHYSIOL, V27, P465
  17. MALLIANI A, 1991, PHARMACOL RES, V24, P43, DOI 10.1016/1043-6618(91)90120-M
  18. MANABE N, 1991, J AUTONOM NERV SYST, V32, P233, DOI 10.1016/0165-1838(91)90117-L
  19. Moraes-Silva IC, 2017, ADV EXP MED BIOL, V999, P139, DOI 10.1007/978-981-10-4307-9_9
  20. Mostarda C, 2010, CLIN EXP PHARMACOL P, V37, P447, DOI 10.1111/j.1440-1681.2009.05327.x
  21. Mostarda C, 2014, AM J TRANSL RES, V6, P320
  22. MW Montera, 2009, Arq. Bras. Cardiol., V93, P2, DOI 10.1590/S0066-782X2009001900001
  23. Negrao CE, 2008, HEART FAIL REV, V13, P51, DOI 10.1007/s10741-007-9057-7
  24. Nobrega ACL, 2001, CLIN AUTON RES, V11, P11, DOI 10.1007/BF02317797
  25. PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161
  26. Ponikowski P, 1997, AM J CARDIOL, V79, P1645, DOI 10.1016/S0002-9149(97)00215-4
  27. Richtsfeld M, 2013, ANESTHESIOLOGY, V119, P412, DOI 10.1097/ALN.0b013e318291c02e
  28. Rocha JA, 2016, AM J PHYSIOL-REG I, V310, pR697, DOI 10.1152/ajpregu.00328.2015
  29. Rodrigues B., 2014, MEDIAT INFLAMM, P1
  30. Rodrigues Bruno, 2017, Motriz: rev. educ. fis., V23, pe101624, DOI 10.1590/s1980-6574201700si0005
  31. Rodrigues B, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/702473
  32. Santos-Almeida FM, 2015, AM J PHYSIOL-HEART C, V308, pH101, DOI 10.1152/ajpheart.00591.2014
  33. Shinlapawittayatorn K, 2013, HEART RHYTHM, V10, P1700, DOI 10.1016/j.hrthm.2013.08.009
  34. Singh Gunveen, 2017, Perm J, V21, P15, DOI 10.7812/TPP/15-240
  35. Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981
  36. Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
  37. Tucci PJF, 2011, ARQ BRAS CARDIOL, V96, P420, DOI 10.1590/S0066-782X2011005000049
  38. Uitterdijk A, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0508-3
  39. Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/59
Artigos e Materiais de Revistas Científicas - ODS/03